Mark Cuban

Mark Cuban argues AI labs like Anthropic and OpenAI cannot immediately replace Lovable and Replit due to their add-on services and localized data. Lovable's CEO states users increasingly view the tool as an 'AI cofounder,' while founders and investors fear competition from large AI models like Claude Code.

Mark Cuban, Paul Kedrosky, and Paul Krugman argue that public backlash against AI stems from its wealth concentration and job displacement impacts, not just cultural or technological fears. Goldman Sachs estimates 15 million U.S. workers could face job displacement during the AI transition, though long-term job creation is expected.

Mark Cuban advised AI companies to spend billions to support towns and cities affected by AI-driven job losses, calling it a 'cost of doing business.' He criticized AI firms for failing to prioritize people and losing public relations battles, urging direct engagement with creatives and workers to address concerns.

Voyager investors have appealed the dismissal of their claims against Mark Cuban and the Dallas Mavericks to the Eleventh Circuit. The case involves allegations related to the Voyager crypto platform.

Politicians are addressing AI regulation for children following failures with social media. Bipartisan efforts focus on age verification laws and penalties for harmful AI interactions, with leaders like Utah's Spencer Cox and Missouri's Josh Hawley advocating for strict measures. The Trump administration has shifted toward supporting age-assurance requirements amid industry scrutiny.

Mark Cuban and physicians are advocating for holding health insurers accountable for care denials that harm patients. The current system enables insurers to avoid responsibility by exploiting the fact that most patients do not appeal these decisions.

ARK Invest CEO Cathie Wood projects Bitcoin to reach $750,000 by 2030, citing generational wealth shifts, institutional adoption, and Bitcoin's role as an insurance policy in emerging markets. She acknowledges criticism but emphasizes Bitcoin's scarcity and low correlation with other assets.

Mark Cuban, a prominent billionaire investor, has sold his Bitcoin holdings, citing underperformance compared to gold and the lack of meaningful breakout applications in the cryptocurrency space as key reasons for his decision.

Mark Cuban has sold most of his Bitcoin holdings, stating it failed to act as an effective hedge against fiat currency weakness and geopolitical turmoil. The billionaire investor cited Bitcoin's poor performance during the U.S.-Iran conflict compared to gold's surge as the breaking point for his confidence in the asset.

Mark Cuban, a prominent billionaire investor, has sold most of his Bitcoin holdings due to disappointment with its performance. The move reflects Cuban's reassessment of his cryptocurrency portfolio strategy.

Mark Cuban revealed he sold most of his Bitcoin holdings after becoming disappointed with the cryptocurrency's failed narrative as a hedge asset. The billionaire entrepreneur's decision reflects his skepticism about Bitcoin's utility as a hedge instrument compared to traditional assets.

Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, mocked Joy Behar on social media after she warned that Americans would "all going to die" if Trump's name was attached to the new TrumpRx prescription drug plan. The exchange escalated tensions on "The View" where co-hosts debated the merits and trustworthiness of the drug-pricing initiative, with some supporting it for lower costs regardless of branding and others expressing skepticism based on Trump's past business ventures.

Tech billionaires like Jeff Bezos and Elon Musk are questioning the value of philanthropy compared to their for-profit companies, marking a shift from earlier charitable pledges. This raises questions about how the new generation of AI-age billionaires will be remembered compared to historical figures like Andrew Carnegie who endowed major institutions. Some experts predict a return to 19th-century style philanthropy focused on broader societal flourishing rather than metrics-driven giving.

Joy Behar criticized Mark Cuban after his meeting with Donald Trump, clashing with co-hosts over their support for Trump's pharmacy venture. Behar called her co-hosts naive for backing the president's plan. The disagreement highlights a divide among the show's hosts.

The View co-hosts debated President Donald Trump's TrumpRx initiative, a plan to lower prescription drug costs, with some expressing skepticism due to Trump's involvement. Joy Behar warned that the plan could have negative consequences, while others argued it could bring down prescription drug costs. The plan partners with private-sector companies like Amazon and Mark Cuban Cost Plus Drugs.

The US Supreme Court declined to hear lawsuits from brand-name pharmaceutical companies against the Medicare drug price negotiation program, and the TrumpRx prescription drug discount platform is expanding with over 600 generic drugs. The expansion is a result of partnerships with Mark Cuban's Cost Plus Drug Company, Amazon Pharmacy, and GoodRx. This development may make remaining legal challenges more difficult for the drug industry.

Mark Cuban and President Donald Trump have partnered to launch TrumpRx.gov, a new initiative aimed at lowering the cost of generic prescription drugs. The partnership comes after a history of heated political attacks between the two. Cuban's company, Mark Cuban Cost Plus Drugs, will work with the Trump administration and other private-sector companies.

President Trump announced the addition of over 600 generic drugs to his drug coupon platform TrumpRx, increasing the number of available drugs by nearly seven times. Mark Cuban joined President Trump to endorse the website. The expansion aims to provide more affordable generics through the platform.

The White House has expanded its prescription drug discount platform, TrumpRx, by adding over 600 generic drugs through partnerships with Cost Plus Drug Co, Amazon Pharmacy, and GoodRx. This expansion aims to provide consumers with a single source for low-cost prescriptions. The partnership is expected to benefit consumers by offering them the lowest possible cost on their prescriptions.

President Donald Trump has announced initiatives to reduce prescription drug costs, but the impact is uncertain and many prices have increased. Americans pay about three times as much as people in other countries for the same drugs. The effectiveness of Trump's efforts remains to be seen.

Mark Cuban stated that OpenAI will not return the $1T it is investing. The investment is likely to be used for development and research. Mark Cuban expressed his confidence in OpenAI's potential.

Mark Cuban warns that five job categories are at risk due to AI adoption, as companies increasingly prioritize cost and productivity of AI systems over human labor. The shift is already underway, driven by corporate decisions to evaluate AI efficiency against human workforce costs.

Mark Cuban's sports fund has secured $450 million in commitments. The fund is led by billionaire investor Mark Cuban, known for his ownership of the Dallas Mavericks. The article mentions photographer Stefani Reynolds from Bloomberg.

Billionaire investor Mark Cuban denied speculation about a potential 2028 White House bid during an interview with Fox News’s Steve Doocy in Pittsburgh, Pennsylvania. Cuban explicitly stated, 'Yeah, not going to happen,' dismissing the rumors.

Mark Cuban, billionaire investor and owner of CostPlusDrugs.com, rejected a presidential bid and announced collaboration with the Trump administration's TrumpRx initiative to reduce healthcare costs. His platform aims to lower drug prices by eliminating middlemen and importing generic medications to Dallas, significantly benefiting patients with chronic illnesses.

Mark Cuban declined to support Kamala Harris running for president in 2028, despite having been one of her surrogates during her 2024 campaign against President Trump. His response came during a Q&A at Politico’s Health Care Summit.